Correlation Between Inhibikase Therapeutics and Scpharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Inhibikase Therapeutics and Scpharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibikase Therapeutics and Scpharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Inhibikase Therapeutics and Scpharmaceuticals, you can compare the effects of market volatilities on Inhibikase Therapeutics and Scpharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibikase Therapeutics with a short position of Scpharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibikase Therapeutics and Scpharmaceuticals.

Diversification Opportunities for Inhibikase Therapeutics and Scpharmaceuticals

0.53

Correlation Coefficient

Inhibikase Therapeutics  Scpharmaceuticals

Very weak diversification

The 3 months correlation between Inhibikase and Scpharmaceuticals is 0.53. Overlapping area represents the amount of risk that can be diversified away by holding Inhibikase Therapeutics and Scpharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Scpharmaceuticals and Inhibikase Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibikase Therapeutics are associated (or correlated) with Scpharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Scpharmaceuticals has no effect on the direction of Inhibikase Therapeutics i.e., Inhibikase Therapeutics and Scpharmaceuticals go up and down completely randomly.

Pair Corralation between Inhibikase Therapeutics and Scpharmaceuticals

Considering the 90-day investment horizon Inhibikase Therapeutics is expected to generate 2.52 times more return on investment than Scpharmaceuticals. However, Inhibikase Therapeutics is 2.52 times more volatile than Scpharmaceuticals. It trades about -0.02 of its potential returns per unit of risk. Scpharmaceuticals is currently generating about -0.06 per unit of risk. If you would invest  306.00  in Inhibikase Therapeutics on December 26, 2024 and sell it today you would lose (69.00) from holding Inhibikase Therapeutics or give up 22.55% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Inhibikase Therapeutics  vs.  Scpharmaceuticals

Inhibikase Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Inhibikase Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's forward-looking signals remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Scpharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Scpharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest uncertain performance, the Stock's basic indicators remain strong and the recent confusion on Wall Street may also be a sign of long-lasting gains for the firm traders.

Pair Trading with Inhibikase Therapeutics and Scpharmaceuticals

The main advantage of trading using opposite Inhibikase Therapeutics and Scpharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibikase Therapeutics position performs unexpectedly, Scpharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Scpharmaceuticals will offset losses from the drop in Scpharmaceuticals' long position.

The idea behind Inhibikase Therapeutics and Scpharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.